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Aim:Weexamined the effects of addingglargine tometformin–sitagliptin (MS + G)or sitagliptin tometformin–
glargine (MG + S) therapy in type 2 diabetic persons uncontrolled after 24-week MS or MG dual therapy.
Methods: Subjects with A1c ≥ 7% on MS or MG treatment were respectively given glargine (0.2 U/kg starting
dose) or sitagliptin (100 mg daily) for 12 weeks. The primary endpoint was number of subjects attaining A1c
goal deﬁned as b7%.
Results:After receiving24-weekMSorMGdual therapy in theoriginal EASIEStudy, 42% (104/248)onMSand68%
(152/224) on MG attained A1c b 7% (p b 0.0001). The reduction in A1c was negatively associated with baseline
fasting bloodglucose (FBG)only in theMGgroup.Reduction inA1cwasnot related tobaselinepostprandial blood
glucose (PPBG) in either the MG or MS group. Amongst 194 eligible patients, 57.7% (n = 111) entered the 12-
week extension trial [MS + G:74/131, 57.3%; MG + S:37/63, 58.7%) with 55 (51.9%) subjects attaining goal
[MS + G:59.2%; MG + S:37.1%] at week 12. The ﬁnal insulin dosage was similar in both groups [MS + G:
0.46 U/kg;MG + S: 0.45 U/kg]with a higher rate of hypoglycemia in theMG + S (6.5 events/patient-year) than
the MS + G group (3.2 events/patient-year), although neither group had severe hypoglycemia.
Conclusion: Inmetformin-treated type2diabetes patients, high fastingBGpredicted greaterA1c reductionswith the
addition of glargine, but not with sitagliptin. In subjects uncontrolled with 6-month dual therapy of MS orMG, 50%
attained A1c b 7%with triple therapy ofMS + G orMG + S in 12 weeks. The increased rate of hypoglycemiawith
MG + S (but not with MS + G) underlines the need to take measures to avoid the hypoglycemia.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
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The Evaluation of insulin glArgine versus Sitagliptin in Insulin-naivE
patients (EASIE) trial compared the efﬁcacy, safety and tolerability of the
basal insulin (insulin glargine), versus the dipeptidylpeptidase-4 (DPP-4)
inhibitor (sitagliptin), in persons with type 2 diabetes previously
uncontrolled with metformin. After 24 weeks of combination treatment,
50% of subjects attained A1c b 7% with a greater A1c reduction achieved
in the metformin plus glargine (MG group, −1.7%) compared to
metformin plus sitagliptin (MS) group (−1.1%, p b 0.001).More subjects
in the MG group attained A1c b 7% than the MS group (68% versus 42%;
p b 0.0001) (Aschner, Chan, Owens, et al., 2012). Subjects not controlled
on MS or MG combination treatment (A1c ≥ 7%) were invited to
participate in a 12-week extension trial with the addition of the other
therapy. We performed a post-hoc analysis on the relationships between
fasting/postprandial blood glucose (FBG/PPBG) on responses to MS/MG
treatment, if any, and the efﬁcacy and safety of triple therapy (MS + Gor
MG + S) in those uncontrolled on dual therapy.
2. Methods
2.1. Study design
This was a 3-month extension of the original EASIE study, with
clinic visits at weeks 0, 4, 8 and 12 and phone calls at weeks 1, 3, 6, 8
and 10. Laboratory data including A1c and lipids were recorded at
weeks 0, 4 and 12. All participants were asked to perform self-
monitoring of blood glucose (SMBG) with measurement of FBG daily
and 7-point SMBG proﬁles at weeks 0, 8 and 12. Body weight was
recorded at weeks 0, 4, 8 and 12. The study was approved by local
ethics committees and conducted in accordance to the Declaration of
Helsinki. Written informed consent was obtained from all participants
before commencement of data collection.
2.2. Study population and procedures
Persons with type 2 diabetes with A1c ≥ 7% on completion of the
24-week original EASIE study (Aschner et al., 2012) were invited to
enter the extension trial although some centers did not participate
due to small number of enrolled or eligible patients at each site and/or
administrative reasons. Subjects in the MG + S subgroup were given
a ﬁxed oral dose of 100 mg sitagliptin once daily taken in the morning
either with or without food and asked to continue to titrate their
insulin glargine dose according to the original study as described
below (Aschner et al., 2012). No change in sitagliptin dose was
allowed during the study. In the MS + G group, participants were
started on an initial subcutaneous dose of 0.2 U/kg for glargine
injected at dinner or bedtime using a preﬁlled SoloSTAR® pen (sanoﬁ-
aventis, Frankfurt, Germany). Subjects were asked to self-titrate
insulin glargine twice-weekly aiming at a self-monitored fasting blood
glucose (SMFBG)of 3.9–5.5 mmol/l (N70and≤100 mg/dl). Thedosewas
decreasedby2 Uif SMFBGwasb4.0mmol/lwithorwithout symptomatic
hypoglycemia, or increasedby2 U if SMFBGwas5.6–7.7 mmol/l orby4 U
if SMFBGwas N7.7 mmol/l, based on the intermediate value of three daily
values of SMFBG. The EASIE international titration committee reviewed
the titration data weekly via a website and the study investigators were
contacted by email if titrationwas inadequate.Minor departures from the
algorithm were allowed.
2.3. Efﬁcacy endpoints
The primary efﬁcacy endpoint was the number of subjects attaining
A1c goal deﬁned as b7%. Secondary endpoints included A1c, SMFBG, 7-
point SMBG proﬁle and mean daily SMBG, hypoglycemia, body weight
and overall safety. During the structured 7-point SMBGproﬁle atweeks 0,
8 and 12, capillary SMBG values were recorded before and 2-h afterbreakfast, lunch and dinner and at bedtime. Mean daily SMBG was
calculated as the mean of the 7-point SMBG proﬁle. Symptomatic
hypoglycemia was deﬁned as typical symptoms with or without
conﬁrmation of SMBG b 4.0 mmol/l. Severe symptomatic hypoglycemia
was deﬁned as symptoms of hypoglycemia, requiring assistance from a
third person for administration of oral carbohydrate, injected glucagon or
other countermeasures togetherwith ameasured SMBG b 2.0 mmol/l or
recovery attributable to the restoration of BG to normal.
2.4. Statistical analysis
2.4.1. Post hoc analysis of 24-week EASIE Study
We ﬁrst explored the relationships between changes in A1c
(ΔA1c) at week 24 and baseline FBG and PPBG in subjects who
completed the original EASIE Trial randomized to the MS and MG
group separately. We then performed logistic regression to identify
predictors for attainment of A1c b 7% at week 24 using independent
variables including treatment assignment (glargine versus sitaglip-
tin), median age (≤54 versus N54 years), median A1c (b8.3 versus
≥8.3%), FBG (b8.8 mmol/L versus ≥8.8 mmol/L) and PPBG
(b10.8 mmol/L versus ≥10.8 mmol/L) at baseline with adjustment
for heterogeneity due to countries. Covariables with signiﬁcance level
of 0.15 were entered and kept in the model for signiﬁcance level of
0.05. Signiﬁcant variables were further tested for interaction and
expressed as odds ratio (OR) with 95% conﬁdence intervals (CIs).
2.4.2. 12-week EASIE Extension trial
In this 12-week extension trial, since participants were not
randomized at baseline of the extension trial, no statistical compar-
ison between subgroups was therefore made. Descriptive summary
statistics were provided for continuous variables and number and
percentage of subjects for categorical variables. Proportions (95% CI)
of persons with primary efﬁcacy variable were reported in the whole
group and subgroups in the modiﬁed intent-to-treat (m-ITT)
population. The m-ITT population included all who received ≥1
dose of the third drug, i.e. glargine in theMS group or sitagliptin in the
MG group and with ≥1 on-treatment assessment of any primary or
secondary efﬁcacy variables. The safety population included all who
received ≥1 dose of the third drug. Descriptive statistics were
provided for secondary efﬁcacy variables and for the rate of
hypoglycemia expressed as event per person-year with 95% CIs.
Treatment-Emergent Adverse Events (TEAEs) were deﬁned as AEs
that developed, worsened or increased in severity from the addition of
the ﬁrst dose of the third drug to 7 days after the last dose. This trial
was registered at ClinicalTrials.gov, NCT00751114.
3. Results
3.1. Predictors for A1c b 7% at the end of the 24-week EASIE Trial
At the end of the 24-week original EASIE Trial, overall 50% of subjects
attained A1c b 7% with 42% (104/248,) from the MS and 68% (152/224)
from the MG group (p b 0.0001). Using regression analysis, the slope of
ΔA1c against FBGwas signiﬁcant in theMG group (p b 0.001) but not in
the MS group (p = 0.5325) with signiﬁcant between-group difference
(p = 0.0304). The slope of ΔA1c against PPBG was not signiﬁcant in
either theMG (p = 0.0970) orMS group (p = 0.2711) (Supplementary
Fig. 1). Table 1 shows the results of the logistic regression analysis to
identify predictors for A1c b 7% including the interaction between
treatment and FBG/PPBG. In model (A) where PPBG was held as an
independent predictor, the MS group was less likely to reach A1c goal
than theMGgroup especially in thosewith high FBG (OR = 0.15) versus
low FBG (OR = 0.36) with signiﬁcant between-group difference
stratiﬁed by FBG (p b 0.001). In the MG group, FBG did not have effect
on A1c response to glargine (OR = 0.9) while MS-treated patients with
high FBG (OR = 0.38) were less likely to be controlled than those
Table 1
Multivariable analysis to identify predictors for A1c b 7% in metformin-treated type 2 diabetic subjects given additional glargine or sitagliptin for 24 weeks. Model 1A included
interactions between treatment and fasting blood glucose and Model 1B included interaction between treatment and postprandial blood glucose.
Predicting factors (Multivariate analysis) OR (95% CI) p-value
Model 1A
Treatment b .0001
Sitagliptin vs Insulin glargine with baseline FBG b 8.8 mmol/L 0.36 (0.18; 0.70)
Sitagliptin vs Insulin glargine with baseline FBG ≥ 8.8 mmol/L 0.15 (0.08; 0.30)
Age at baseline 0.0114
N54 years vs ≤54 years with baseline A1c b 8.3% 1.05 (0.52; 2.08)
N54 years vs ≤54 years with baseline A1c ≥ 8.3% 3.38 (1.75; 6.53)
A1c value at baseline 0.0001
≥8.3%% vs b 8.3%% with baseline age ≤54 year 0.20 (0.10; 0.40)
≥8.3%% vs b 8.3%% with baseline age N54 years 0.65 (0.33; 1.30)
FBG at baseline 0.0412
≥8.8 mmol/L vs b8.8 mmol/L with Insulin glargine 0.90 (0.44; 1.84)
≥8.8 mmol/L vs b8.8 mmol/L with Sitagliptin 0.38 (0.19; 0.75)
PP BG at baseline
≥10.8 mmol/L vs b10.8 mmol/L 0.42 (0.25; 0.69) 0.0006
Age at baseline × A1c value at baseline 0.0132
Treatment arm × FPG value at baseline 0.0767
Number of patients included in the analysis 429
Test of adequacy of model: Hosmer–Lemeshow 0.4475
Quality of predictive model: AUC 0.796
Model 1B
Treatment b .0001
Sitagliptin vs Insulin glargine with baseline PPBG b 10.8 mmol/L 0.22 (0.11; 0.44)
Sitagliptin vs Insulin glargine with baseline PPBG ≥10.8 mmol/L 0.24 (0.13; 0.45)
Age at baseline 0.0122
N54 years vs ≤54 years with baseline A1c b 8.3% 1.05 (0.53; 2.09)
N54 years vs ≤54 years with baseline A1c ≥ 8.3% 3.31 (1.73; 6.35)
A1c value at baseline 0.0001
≥8.3%% vs b 8.3%% with baseline age ≤54 year 0.21 (0.10; 0.41)
≥8.3%% vs b 8.3%% with baseline age N54 years 0.65 (0.33; 1.29)
FBG at baseline
≥8.8 mmol/L vs b 8.8 mmol/L 0.57 (0.34; 0.95) 0.0296
PPBG at baseline 0.0006
≥10.8 mmol/L vs b10.8 mmol/L with Insulin glargine 0.40 (0.19; 0.83)
≥10.8 mmol/L vs b10.8 mmol/L with Sitagliptin 0.43 (0.23; 0.82)
Age at baseline × A1c value at baseline 0.0145
Treatment arm × PPBG value at baseline 0.8607
Number of patients included in the analysis 429
Test of adequacy of model: Hosmer–Lemeshow 0.9241
Quality of predictive model: AUC 0.792
Odds Ratio (95%Wald Conﬁdence Interval; PPBG = post prandial blood glucose; FBG = fasting blood glucose. Stepwise method was used for Step 1 and 2 with signiﬁcance level of
0.15 for entry and signiﬁcance level of 0.05 for stay. In Step 1, treatment was forced into themodel with all other covariates entered or excluded from themodel according toWald chi
square test. In Step 2, interaction terms were introduced according to Wald chi square test. The factor country was kept for adjustment in the model but not presented.
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(p = 0.08). Older subjects with high A1c were 3.8-fold more likely than
their young counterparts to attain A1c goal. Subjects with high A1c were
not likely to attain A1c goal although the older subjects (OR = 0.65)
were more likely to be controlled than the young subjects (OR = 0.20)
with signiﬁcant age × A1c interaction (p = 0.0132). Inmodel (B)which
identiﬁes FBG as an independent predictor, the MS group was less
likely to attain A1c goal than the MG group, whether PPBG was high
(OR = 0.24) or low (OR = 0.22). In subjects with high PPBG, glycemic
control was not likely in either the MG (OR = 0.40) or MS (OR = 0.43)
group compared to those with low PPBG. Older subjects with high A1c
were 3.3-fold more likely to attain A1c goal than the young ones while
subjects with high A1c were not likely to achieve control although
the older subjects (OR = 0.65) had a higher odds to do so than the
young subjects (OR = 0.21) with signiﬁcant age × A1c interaction
(p = 0.0145).
3.2. Baseline characteristics of patients entering the 12-week extension phase
Amongst the 515 randomized patients (250 to glargine and 265 to
sitagliptin), 445 patients completed the 24-week original EASIE study.
Of these, 131/233 (56.2%) treated with MS combination and 63/212(29.7%) treated with MG combination remained uncontrolled with
A1c ≥ 7% (Fig. 1) (Aschner et al., 2012). In the MS group, 75 of 131
eligible (57.3%) persons received MS + G combination therapy while
37 of the 63 eligible persons (58.7%) in the MG group received
MG + S combination treatment, giving a total of 112 subjects for
safety analysis in the 12-week extension trial. One person withdrew
from the study before receiving additional glargine, with 111
remaining in the m-ITT population for efﬁcacy analysis (74 in
MS + G group and 37 in MG + S group).
Table 2 shows the characteristics of the participants at enrolment
to the original EASIE study and their glycemic control at the end of the
24-week study period, prior to entry to the 12-week extension trial.
Amongst those who entered the extension trial, 20% had one or more
diabetic complications, and more than 85% were taking at least one
concomitant medication for other risk factors. The 82 eligible non-
participants had lower mean A1c at baseline, mean daily SMFBG,
mean 7-point SMBG including SMBG at dinner and bedtime as well as
diastolic blood pressure than participants of the EASIE extension trial
(data not shown). Participation was entirely voluntary. The reasons
for the relatively high non-participation rate were mainly due to too
few enrolled or eligible subjects for the extension trial at each site or
other administrative reasons.
Fig. 1. A ﬂow chart showing the disposition of metformin-treated type 2 diabetic subjects who have completed 24-week treatment with additional glargine or sitagliptin invited to
participate in a 12-week extension trial for triple treatment using metformin, glargine and sitagliptin.
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In the m-ITT population, after 12 weeks of triple treatment with
MS + G or MG + S, the overall mean A1c levels fell from 8.0% to 7.2%
(Fig. 2A) with a mean A1c change of−0.8% (Table 3) and attainment of
A1c b 7% in 55 patients (51.9%). On subgroup analysis, in the MS + G
group, the A1c fell from 8.1% to 7.1% with a change of −1.0% whereas
in theMG + Sgroup, the A1c fell from7.8% to 7.4%with anA1c change of
−0.4% (Fig. 2A and Table 2). In the MS + G group, 42 (59.2%) and in the
MG + S group, 13 (37.1%) attained A1c b 7% at the end of the 12 week
extension trial.
The improvement in A1c was accompanied by reductions in SMFBG
and 7-point SMBG proﬁle. After 12 weeks, in the m-ITT group, the mean
SMFBG fell from 8.0 mmol/l to 6.1 mmol/l (Fig. 2B) and the mean daily
SMBG, from9.2 mmol/l to 7.5 mmol/l (Fig. 2C)with concomitant changes
at all times during the 7-point SMBGmonitoring (Fig. 3A). In theMG + S
group, mean SMFBG was 6.1 mmol/l and did not change further while inTable 2
Clinical characteristics of type 2 diabetic subjects at enrolment and after 24 week combinat
extension trial with addition of glargine (MS + G) or sitagliptin (MG + S) for 12 weeks.
m-ITT group (N = 1
At entry of the original 24-week EASIE trial
Age, years 52.4 (9.3)
Women, n (%) 56 (50.5)
Duration of diabetes, years 4.1 (2.0; 8.3)
Treatment with oral anti-diabetic drugs, years 2.5 (1.1; 6.7)
Daily dose of metformin, mg 1875 (519)
At baseline of the 12-week EASIE Extension trial
Body weight, kg 84.6 (21.0)
Body mass index, kg/m2 31.3 (5.2)
A1c, % 8.0 (1.0)
A1c, mmol/mol 64 (11)
Self monitored 7-point blood glucose, mmol/l 8.0 (2.1)
Self monitored fasting blood glucose, mmol/l 9.2 (1.8)
Data are expressed as mean (SD), median (interquartile range) or n (%).the MS + G group, SMFBG declined from 9.0 mmol/l to 6.0 mmol/l
(Fig. 2B). The mean 7-point SMBG values in the MG + S group fell from
8.3 mmol/l to 7.6 mmol/l (Fig. 2C) whereas in the MS + G subgroup,
values declined from9.6 to 7.5 mmol/l (Fig. 2C). Fig. 3B and C showed the
7-point SMBG proﬁles which improved in both groups with numerically
greater reduction in the MS + G than the MG + S group (Table 3).
In the MS + G group, the dose increased from 0.19 ± 0.03 U/kg to
0.46 ± 0.21 U/kg at the end of the 12-week extension trial. In the
MG + S group, the respective dose was 0.45 ± 0.18 U/kg which was
similar to the dose at 12-week after insulin initiation in the original
EASIE trial and remained stable during the extension trial (Fig. 4).
3.4. Safety
Themeanbodyweight increased by1.2 kg in thewhole groupwith an
increase of 1.3 kg in the MS + G group and 0.9 kg in the MG + S group
(Table 3). Serum fasting triglyceride declined in both groups with aion treatment with metformin–glargine or metformin–sitagliptin prior to the 12-week
11) MG + S (n = 37) MS + G (n = 74)
51.5 (9.5) 52.9 (9.3)
20 (54.1) 36 (48.6)
3.9 (1.9; 8.7) 4.2 (2.2; 8.3)
1.9 (0.9; 4.3) 3.2 (1.1; 7.1)
1746 (530) 1939 (504)
86.0 (21.5) 83.9 (20.8)
32.1 (5.8) 30.8 (4.8)
7.8 (0.9) 8.1 (1.1)
62 (10) 65 (12)
6.1 (1.2) 9.0 (1.8)
8.3 (1.4) 9.6 (1.8)
Fig. 2. Glycated haemoglobin (A1c, Panel A), self monitored fasting blood glucose
(SMFBG Panel B) and daily SMBG (Panel C) in type 2 diabetic subjects after 24-week
treatment with metformin–glargine or metformin–sitagliptin combination treatment
(baseline) followed by addition of the other drug in the modiﬁed intention-to-treat
(mITT) group and subgroups of subjects treated with additional sitagliptin or glargine
for 12 weeks.
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group. Table 3 shows the rates of symptomatic hypoglycemia in the ITT
populationwithahigher event rate of hypoglycemia in theMG + Sgroup
(6.5 per patient-year) compared to 3.2 per patient-year in the MS + G
group. During the ﬁrst 8 weeks of active insulin titration, there were 32
events in theMG + Sgroup (n = 37)witha total exposureperiodof4.47
patient-years, giving anevent rate of 7.16perpatient-year. In theMS + G
group (n = 75) with a total exposure period of 8.9 patient-years, there
were 44 events with an event rate of 4.94 per patient-year. Between
weeks 8 and 12, therewere 29 eventswith a total exposure period of 2.69
patient-years and an event rate of 10.78 per patient-year in the MG + S
group. In the MS + G group, there were 15 events with a total exposure
period of 5.45 patient-years and 2.75 events per patient-year.
A total of 41 patients (36.6%) experienced ≥1 TEAE. The most
frequent TEAEs reported were inﬂuenza, naso-pharyngitis and
urinary tract infection reported by 4 persons (3.6%). Two subjects
presented with serious TEAEs, one due to right ventricular failure,
considered to be possibly related to sitagliptin and the other due to
endometrial cancer which was not considered to be drug-related.
There was no TEAE resulting in treatment discontinuation or deaths
during the 12-week extension trial.4. Discussion
The 24-week original EASIE trial has provided the ﬁrst comparative
data betweenglargine and sitagliptin, aDDP4-inhibitor, in type2diabetic
subjects who failed metformin with 50% of them attaining A1c b 7%
(Aschner et al., 2012). In this 12-week extension trial, 50% of subjects
who failedMSorMGtherapyattainedA1cgoalwhengiven triple therapy
(MS + G or MG + S), with a low risk of severe hypoglycemia.
Despite their different mechanisms of actions, all classes of anti-
diabetic drugs including insulin are efﬁcacious in reducing blood
glucose (Tahrani, Bailey, Del Prato, & Barnett, 2011). In a recent meta-
analysis, the magnitude of reduction in A1c across 10 classes of anti-
diabetic drugs closely correlated with baseline A1c (DeFronzo,
Stonehouse, Han, & Wintle, 2010). This might be in part due to the
amelioration of glucotoxicity with possible restoration of beta cell
function, thence the importance of optimizing glycemic control
during early stage of disease to preserve beta cell function (Weng,
Li, Xu, et al., 2008). In the original EASIE Trial which enrolled subjects
with type 2 diabetes who failed metformin monotherapy, the mean
disease duration was only 3 years. Less than 10% of the original cohort
had cardiovascular complications in whom the risk–beneﬁt ratio of
intensive glycemic control was expected to be favorable (Del Prato,
2009; Gerstein, Miller, Byington, et al., 2008).
Since glargine predominantly lowers FBG by suppressing hepatic
glucoseproductionwhile sitagliptin tends to lower PPBGbyaugmenting
meal-stimulated insulin secretion and suppressing glucagon production
(DeFronzo et al., 2010), we explored the possible impacts of FBG and
PPBG on treatment responses in theMS andMGgroups. However, using
regression analysis, only FBG was associated with A1c changes in the
MGbut not theMS groupwhile PPBG did not bear any relationshipwith
A1c changes in both groups. Given the potent effect of glargine in
lowering FBG, more patients in the MG (68%) than the MS (42%) group
attained A1c goal at the end of the 24-week original EASIE trial.
In our multivariable analysis, metformin-treated subjects with
high baseline A1c, FBG and PPBG were not likely to attain A1c goal
despite addition of glargine or sitagliptin. Although subjects with
high FBG treated with glargine were more likely to respond than
sitagliptin, we did not detect signiﬁcant interaction between
treatment and FBG/PPBG. Of note, older subjects with A1c ≥ 8.3%
were 3.3-fold more likely to attain A1c goal than their young
counterparts with poor control with signiﬁcant age × A1c interac-
tion. In observational surveys, young age was consistently associated
with suboptimal glycemic control with high non-compliance rates
(Yeung et al., 2014; Gregg, Karter, Gerzoff, et al., 2010). In these
subjects who might have competing priorities or low motivation for
long term therapy, individualized psychological–behavioral strate-
gies in addition to medications may be needed for disease control.
Although subjects with high A1c generally had greater reduction in
A1c (DeFronzo et al., 2010), given amean reduction of 0.4%–0.8% in A1c
with most oral anti-diabetic drugs (McIntosh, Cameron, Singh, et al.,
2011), many type 2 diabetic persons required multiple drugs to attain
A1c goal (Tong et al., 2008). Thus, during thedesignof the original EASIE
trial protocol, we had built in an extension trial to explore the effects of
triple therapy in those who failed MG or MS combination treatment.
Over 50% of those eligible from the MS and MG groups participated in
the extension trial, with the non-participants being younger and having
better glycemic control than the participants. In this extension trial, we
did not intend to compare efﬁcacy between the MS + G and MG + S
triple therapy but provided a descriptive analysis to inform readers
regarding the effects of triple therapy in uncontrolled subjects on
MS + G or MG + S dual therapy. Besides, it would not have been
possible to re-randomize the entire group which was either redundant
for those who had attained goal or unethical for those who had not
reached goal. Given the fact that the non-participants had better
glycemic control than the participants and that most centers did not
participate in the extension trial due to administrative reasons, addition
Table 3
Changes in efﬁcacy and safety measures in type 2 diabetic subjects uncontrolled after 24-week combination treatment with metformin–glargine or metformin–sitagliptin followed
by addition of the other drug in the modiﬁed intention-to-treat (mITT) group and subgroups of subjects treated with additional Glargine (MS + G) or Sitagliptin (MG + S) for
12 weeks.
m-ITT group (N = 111) MG + S (n = 37) MS + G (n = 74)
Efﬁcacy measures
A1c, % −0.8 [−1.0; −0.6] −0.4 [−0.8; 0.0] −1.0 [−1.2; −0.8]
Self monitored fasting BG, mmol/l −2.0 [−2.4; −1.5] −0.0 [−0.3; 0.3] −3.0 [−3.4; −2.5]
Mean daily SMBG, mmol/l −1.6 [−2.0; −1.3] −0.7 [−1.1; −0.2] −2.1 [−2.5; −1.7]
7-Point SMBG, mmol/l
Before breakfast −1.9 [−2.3; −1.5] −0.2 [−0.6; 0.2] −2.7 [−3.2; −2.3]
After breakfast −1.9 [−2.4; −1.4] −0.7 [−1.5; 0.1] −2.5 [−3.2; −1.9]
Before lunch −1.5 [−2.0; −1.0] −0.5 [−1.3; 0.3] −2.0 [−2.6; −1.3]
After lunch −1.5 [−1.9; −1.0] −0.7 [−1.4; −0.0] −1.9 [−2.5; −1.2]
Before dinner −1.4 [−1.9; −0.9] −1.0 [−1.9; −0.2] −1.6 [−2.2; −1.0]
After dinner −1.4 [−1.9; −0.9] −0.7 [−1.4; −0.0] −1.8 [−2.5; −1.1]
Bedtime −2.0 [−2.6; −1.4] −1.1 [−2.0; −0.2] −2.4 [−3.1; −1.6]
Body weight, kg 1.2 [0.7, 1.6] 0.9 [0.1, 1.7] 1.3 [0.8, 1.8]
Total cholesterol, mmol/l −0.15 [−0.34; 0.04] −0.03 [−0.38; 0.32] −0.21 [−0.43; 0.01]
LDL cholesterol, mmol/l −0.02 [−0.12; 0.16] −0.07 [−0.23; 0.38] −0.01 [−0.16; 0.14]
HDL cholesterol, mmol/l 0.02 [−0.02; 0.06] −0.06 [−0.13; 0.00] 0.06 [−0.01; 0.10]
Triglycerides, mmol/l −0.49 [−0.80; −0.18] 0.08 [−0.17; 0.34] −0.77 [−1.21; −0.33]
All participants (N = 112) MG + S (n = 37) MS + G (n = 75)
Safety measures, Events per patient-year
All symptomatic hypoglycemia 4.3 [3. 6; 5.1] 6.5 [4.9; 8.3] 3.2 [2.4; 4.1]
Symptomatic hypoglycemia with SMBG ≤3.9 mmol/l 3.4 [2.8; 4.2] 4.6 [3.3; 6.1] 2.8[2.1; 3.7]
Nocturnal symptomatic hypoglycemia 1.2 [0.8; 1.7] 1.9 [1.1; 3.0] 0.9 [0.5; 1.4]
Nocturnal symptomatic hypoglycemia with SMBG ≤3.9 mmol/l 1.1 [0.7; 1.6] 1.9 [1.1; 3.0] 0.7 [0.4; 1.2]
Severe symptomatic hypoglycemia 0 [0.0; 0.1] 0 [0.0; 0.4] 0 [0.0; 0.2]
Severe nocturnal symptomatic hypoglycemia 0 [0.0; 0.1] 0 [0.0; 0.4] 0 [0.0; 0.2]
Symptomatic hypoglycemia with SMBG ≤3.1 mmol/l 1.3 [0.9; 1.7] 1.4 [0.7; 2.4] 1.2 [0.7; 1.8]
Nocturnal symptomatic hypoglycemia with SMBG ≤3.1 mmol/l 0.4 [0.2; 0.7] 0.4 [0.1; 1.1] 0.4 [0.1; 0.8]
Data are mean [95% CI]. HDL, high density lipoprotein; LDL, low density lipoprotein; SMBG, self-monitored blood glucose. Mean daily SMBG based on 7-point blood glucose proﬁle.
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introduce systematic bias.
At the end of the 24-week original EASIE trial, subjects in the MS
group had higher A1c and lower body weight that those in the MG
group. The addition of glargine to the MS group resulted in a 1%
reduction inA1c accompanied by a reduction in SMFBGandmeanSMBG
during the 7-point SMBGproﬁle. Byweek 12, A1c control had stabilized
with a dosage of 0.46 U/kg. Thiswas similar to the glarginedosage in the
MG group at week 12 during the original EASIE trial with a 1.7% A1c
reduction and a stable dosage thereafter. Despite similar dosages, the
different A1c responses might be due to the higher A1c level in the MG
group at randomization (8.5%) compared to 8.1% after 24 weeks of MS
treatment followed by the addition of glargine in the extension trial.
In the MG group with an A1c of 7.8% at the end of the original
EASIE trial, the addition of sitagliptin resulted in a 0.4% reduction in
A1c. This degree of A1c reduction was within the range in most
comparative trials of DPP4 inhibitors (Tahrani et al., 2011). In the
SAVOR study, saxagliptin reduced A1c by 0.3% compared to placebo in
subjects with a baseline A1c of 8% (Scirica et al., 2013). The latter was
comparable to 7.8% in our subjects after 24 weeks of MG combination
therapy. During this 12-week extension trial, the rate of hypoglycemia
was considerably higher in the MG + S group which was not
anticipated. This was likely to be due to multiple factors, such as the
lower A1c of 7.8% in the MG group compared to 8.1% in the MS group
at the end of 24-week and the possible recovery of insulin secretion
with better glycemic control in the MG group (Weng et al., 2008),
further augmented by the introduction of sitagliptin. Since we had not
introduced a ﬁxed dose reduction of glargine at the time when
sitagliptin was introduced, the investigator could only down titrate
the dosage of glargine when hypoglycemia occurred. Besides, the
dosage of sitagliptin (100 mg daily) was ﬁxed in the MG + S group
compared to the dosage titration of glargine in the MS + G group.
Although DPP4 inhibitors are associated with low risk of hypoglyce-
mia (McIntosh et al., 2011), this side effect is not uncommon in thosetreated with insulin or sulphonylureas (Barnett et al., 2013),
especially with a low A1c (Krobot, Ferrante, Davies, et al., 2012).
Given the considerable phenotypic heterogeneity of type 2
diabetes, many experts and professional bodies emphasized the
need to individualize treatment goals and strategies (Pozzilli, Leslie,
Chan, et al., 2010; Raz, Riddle, Rosenstock, et al., 2013). Long term
trials using glargine (The ORIGIN Trial investigators, Gerstein, Bosch,
et al., 2012) and DPP4 inhibitors (Scirica et al., 2013; White, Cannon,
Heller, et al., 2013) have now conﬁrmed their cardiovascular safety.
Although obesity is often an accompanying feature, beta cell
dysfunction remains a hallmark in type 2 diabetes (Kahn, 2004).
Thus, despite the minor weight gain and hypoglycemic episodes, in
metformin-treated subjects with short disease duration and few
comorbidities, intensive glycemic control by adding glargine and/or
DPP4 inhibitors, offers an additional option to control hyperglycemia.
In this post-hoc analysis of the original EASIE study, metformin-
treated subjects over the age of 54 and those given additional glargine
were most likely to reach A1c goal. Subjects with high FBG, PPBG and
A1c were not likely to reach goal although those with high FBG
(≥8.8 mmol/L) weremore likely to respond to glargine than sitagliptin,
while sitagliptin-treated patients with low FBG were more likely to
respond than thosewith high FBG. In subjectswho failed either the dual
therapy of MS or MG, triple therapy of MSG or MGS would further
improve glycemic control although in MG-treated patients, the dosage
of glargine should be reduced by 20%–30% or a lower dosage of
sitagliptin should be used with increased SMBG to avoid hypoglycemia.
5. Conclusion
In type 2 diabetic subjects uncontrolled on dual therapy of MS or
MG, 50% attained A1c b 7%with triple therapy in 12 weeks. Together
with 50% response rate with dual therapy of MS or MG, the majority
of type 2 diabetic subjects with short disease duration, uncontrolled
on metformin monotherapy, could attain A1c goal with additional
Fig. 3. Baseline and 12-week 7-point self-monitored blood glucose (SMBG) proﬁle in type 2 diabetic subjects after 24-week combination treatment with metformin–glargine or
metformin–sitagliptin followed by addition of the other drug in the modiﬁed intention-to-treat (mITT) group (panel A) and subgroup of subjects treated with additional sitagliptin
or (panel B) glargine (panel C) for 12 weeks.
Fig. 4. Insulin dosage (U/kg) in type 2 diabetic subjects uncontrolled with metformin–
glargine or metformin–sitagliptin combination treatment after 24 weeks with addition
of sitaglipin or glargine respectively for 12 weeks.
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and SMBG.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2014.08.007.
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